



**International
Standard**

ISO 17099

**Radiological protection —
Performance criteria for
laboratories using the cytokinesis-
block micronucleus (CBMN) assay
in peripheral blood lymphocytes for
biological dosimetry**

*Radioprotection — Critères de performance pour les
laboratoires pratiquant la dosimétrie biologique par l'analyse
des micronoyaux par blocage de la cytotérièse (CBMN) dans les
lymphocytes du sang périphérique*

**Second edition
2024-06**

This document is a preview generated by EMS



COPYRIGHT PROTECTED DOCUMENT

© ISO 2024

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

	Page
Foreword	v
Introduction	vii
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 CMBN assay methodology used in this document	3
4.1 General.....	3
4.2 Requests for analysis and blood sampling.....	3
5 Responsibility of the requestor	3
6 Responsibility of the service laboratory	4
6.1 Setup and sustainment of the quality assurance program.....	4
6.2 Responsibility during service.....	4
7 Confidentiality of personal information	5
7.1 Overview.....	5
7.2 Applications of the principle of confidentiality.....	5
7.2.1 Delegation of responsibilities within the laboratory.....	5
7.2.2 Requests for analysis.....	6
7.2.3 Transmission of confidential information.....	6
7.2.4 Anonymity of samples.....	6
7.2.5 Reporting of results.....	6
7.2.6 Storage.....	6
7.2.7 Data security plan.....	6
8 Laboratory safety requirements	6
8.1 Overview.....	6
8.2 Microbiological safety requirements.....	7
8.3 Chemical safety requirements.....	7
8.4 Optical safety requirements.....	8
8.5 Safety plan.....	8
9 Sample processing	8
9.1 Culturing.....	8
9.2 Staining.....	10
9.3 Microscopy.....	10
9.4 Scoring of slides.....	10
9.4.1 General.....	10
9.4.2 Criteria for scoring.....	10
9.4.3 Scoring data sheets.....	11
9.5 Automated analysis.....	11
10 Calibration source(s), calibration curve, and minimum detectable dose	11
10.1 Calibration source(s).....	11
10.2 Calibration curve.....	11
10.3 Background MN frequency.....	12
10.4 Comparison with the background level: Characterisation of the minimum detectable dose.....	13
11 Accidental exposure involving few individuals	15
11.1 Procedure for scoring MN in BNCs.....	15
11.1.1 Coding of samples and slides.....	15
11.1.2 Scoring techniques.....	16
11.1.3 Laboratory scoring expertise.....	16
11.2 Criteria for converting a MN yield into an estimate of absorbed dose.....	16
11.2.1 Overview.....	16

ISO 17099:2024(en)

11.2.2	Comparison with controls	16
11.2.3	Confidence limits on the number of MN	16
11.2.4	Calculation of absorbed dose for whole-body exposures	16
11.2.5	Calculation of uncertainty on absorbed dose	17
11.2.6	Acute and non-acute exposure cases	17
11.2.7	Testing the distribution of MN per BNC	18
11.2.8	Other exposure scenarios	18
11.3	Reporting of results	18
11.3.1	General	18
11.3.2	Content of the report (see Annex D for a standard form)	18
11.3.3	Interpretation of the results	19
12	Population triage	19
12.1	General	19
12.2	Use of a CBMN assay network for large scale exposures	19
12.3	Procedure for scoring MN in BNCs	20
12.4	Criteria for converting a MN yield into an estimate of absorbed dose	20
12.5	Reporting of results	20
13	Quality assurance and quality control	20
13.1	Overview	20
13.2	Specific requirement	20
13.2.1	General	20
13.2.2	Performance checks by laboratory inter-comparisons	20
13.2.3	Periodical performance check of scorer qualification	21
13.2.4	Performance checks of sample transport integrity	21
13.2.5	Performance checks of sample integrity by service laboratory	21
13.2.6	Performance checks for instrumentation	21
13.2.7	Performance checks of sample protocol	22
13.2.8	Performance checks of sample scoring	22
13.2.9	Performance checks of dose and confidence limits estimation	22
13.2.10	Performance checks for result report generation	22
Annex A (informative)	Sample data sheet for recording MN in BNCs	23
Annex B (informative)	Instructions for requestor (sample)	24
Annex C (informative)	Sample questionnaire	25
Annex D (informative)	Sample of report for single assessment	27
Annex E (informative)	Sample group report	29
Annex F (informative)	Decision threshold and detection limit	31
Bibliography		34

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO document should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 85, *Nuclear energy, nuclear technologies, and radiological protection*, Subcommittee SC 2, *Radiological protection*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 430, *Nuclear energy, nuclear technologies and radiological protection*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This second edition cancels and replaces the first edition (ISO 17099:2014), which has been technically revised.

The main changes are as follows:

- minor edits to text throughout;
- reorganization of document to better harmonize with other biological dosimetry standards;
- addition of [7.2.7](#) on data security plan;
- additional requirements added for the report on the conditions of the exposure for the calibration curve in [10.2](#);
- relaxation of the number of individuals required for each age group for establishing background micronucleus frequency, leaving the determination up to the head of the laboratory ([10.3](#));
- addition of details on determining the minimal resolvable dose ([10.4](#)), the absorbed dose ([11.2.4](#)) and the uncertainty ([11.2.5](#));
- removal of reference to coefficient of variance when determining scoring expertise, focussing on the use of 95 % confidence intervals to determine expertise ([11.1.3](#));
- addition of reference to other exposure scenarios ([11.2.8](#));
- removal of Annex on automated micronuclei scoring as it was deemed outside of the scope of the standard;
- addition of a sample group report (see [Annex E](#));

ISO 17099:2024(en)

- addition of a detailed annex (see [Annex F](#)) for calculating the decision threshold and detection limit along with a sample calculation and R script for performing these calculations.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

This document is a preview generated by EVS

Introduction

The purpose of this document is to define the use of the cytokinesis-block micronucleus (CBMN) assay with human peripheral blood lymphocytes for biological dosimetry of exposure to ionizing radiation. This assay is intended to be applied for accidental or malevolent exposures involving

- a) up to a few casualties to provide individual whole-body dose estimates, or
- b) in a triage mode to populations to provide rapid, lower accuracy dose estimates for individuals that can be improved with more accurate analysis at a later time.

The CBMN assay is an alternative cytogenetic technique, which is possibly simpler and faster to perform than the dicentric assay^{[1][2]}. It is also routinely used to demonstrate exposure to genotoxic agents, other than ionizing radiation, which is not covered in this document. Although culture of the blood samples is slightly longer than for dicentrics, the scoring of micronuclei (MN) in binucleated lymphocytes is easier.

As was done with the dicentric assay, the CBMN assay has been adapted for the emergency triage of large-scale multi-casualty nuclear or radiological incident. The blood volume required for a sufficient number of scorable binucleated cells (BNCs) is similar to that required for the dicentric assay. Again, the faster counting speed for MN compensates for the extended culture time. However, it has to be considered that factors such as age, sex, diet and environmental mutagens can have an influence on the results particularly after low dose exposures^{[3][4][5]}. In addition, the CBMN assay can be performed in an automated mode using various cytometric technologies but these are outside the scope of this document.

This document provides a guideline on how to perform the CBMN assay for dose assessment using documented and validated procedures. Dose assessment using the CBMN assay has relevance in medical management, radiation-protection management, record keeping, and medical/legal requirements. This document is divided into two parts, according to the use of CBMN assay: radiation exposure of a few individuals or population triage in a large radiological or nuclear event.

A part of the information in this document is contained in other international guidelines and scientific publications, primarily in the International Atomic Energy Agency's (IAEA) technical reports series on biological dosimetry. However, this document expands and standardizes the quality assurance and quality control, the criteria of accreditation and the evaluation of performance. This document is generally in conformity with ISO/IEC 17025^[6] with particular consideration given to the specific needs of biological dosimetry. The expression of uncertainties in dose estimations given in this document complies with ISO/IEC Guide 98-3^[15] (former GUM) and the ISO 5725 (all parts)^[7].

Radiological protection — Performance criteria for laboratories using the cytokinesis-block micronucleus (CBMN) assay in peripheral blood lymphocytes for biological dosimetry

1 Scope

This document gives guidance on

- a) confidentiality of personal information for the customer and the laboratory,
- b) laboratory safety requirements,
- c) calibration sources and calibration dose ranges useful for establishing the reference dose-response curves that contribute to the dose estimation from CBMN assay yields and the detection limit,
- d) performance of blood collection, culturing, harvesting, and sample preparation for CBMN assay scoring,
- e) scoring criteria,
- f) conversion of micronucleus frequency in BNCs into an estimate of absorbed dose,
- g) reporting of results,
- h) quality assurance and quality control, and
- i) informative annexes containing sample instructions for customers, sample questionnaire, a microscope scoring data sheet, and a sample report.

This document excludes methods for automated scoring of CBMN.

2 Normative references

There are no normative references in this document.

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

3.1

background frequency

background level

spontaneous yield (or number) of MN in BNCs recorded in control samples or individuals who are not abnormally exposed to genotoxins including ionizing radiation